In this study, among the 77 bladder cancer patients, the TWIST1/Vimentin positivity was significantly high, reaching 77.9%, whereas, in individuals with other urological malignancies, the positivity rate was only 18.5%. The gene discussed is VIM; the disease is urinary bladder cancer.